In the latest trading session, 0.83 million Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares changed hands as the company’s beta touched 0.09. With the company’s most recent per share price at $0.60 changing hands around $0.0 or -0.05% at last look, the market valuation stands at $75.50M. KPTI’s current price is a discount, trading about -183.33% off its 52-week high of $1.70. The share price had its 52-week low at $0.53, which suggests the last value was 11.67% up since then.
Analysts gave the Karyopharm Therapeutics Inc (KPTI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.57. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended KPTI as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Karyopharm Therapeutics Inc’s EPS for the current quarter is expected to be -0.26.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
Instantly KPTI was in red as seen in intraday trades today. With action -3.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -11.56%, with the 5-day performance at -3.00% in the red. However, in the 30-day time frame, Karyopharm Therapeutics Inc (NASDAQ:KPTI) is -13.09% down.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 88.0% from its recent market value. According to analyst projections, KPTI’s forecast low is 3 with 14 as the target high. To hit the forecast high, the stock’s price needs a -2233.33% plunge from its current level, while the stock would need to soar -400.0% for it to hit the projected low.
Karyopharm Therapeutics Inc (KPTI) estimates and forecasts
Year-over-year growth is forecast to reach 2.45% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 34.82M. 6 analysts are of the opinion that Karyopharm Therapeutics Inc’s revenue for the current quarter will be 36.99M. The company’s revenue for the corresponding quarters a year ago was 33.13M and 42.79M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 5.10%. The estimates for the next quarter sales put growth at -13.55%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.91%. The 2025 estimates are for Karyopharm Therapeutics Inc earnings to increase by 3.38%, but the outlook for the next 5-year period is at 34.75% per year.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s Major holders
PALO ALTO INVESTORS LP holds the second largest percentage of outstanding shares, with 4.2157% or 5.1 million shares worth $4.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. With 3.42 shares estimated at $2.05 million under it, the former controlled 2.71% of total outstanding shares. On the other hand, Vanguard Explorer Fund, Inc. held about 1.59% of the shares, roughly 2.01 shares worth around $1.2 million.
